TRC-150094

TRC-150094
Identifiers
	IUPAC name 3-(4-((7-Hydroxy-6-methyl-2,3-dihydro-1H-inden-4-YL)methyl)-3,5-dimethyl-1H-pyrazol-1-yl)propanoic acid;
JSmol)	Interactive image;
	SMILES CC1=CC(=C2CCCC2=C1O)CC3=C(N(N=C3C)CCC(=O)O)C;
	InChI InChI=1S/C19H24N2O3/c1-11-9-14(15-5-4-6-16(15)19(11)24)10-17-12(2)20-21(13(17)3)8-7-18(22)23/h9,24H,4-8,10H2,1-3H3,(H,22,23); Key:OFUOCIUIWKDKPA-UHFFFAOYSA-N;

TRC-150094 is a drug which acts as a metabolic modulator which restores metabolic flexibility. It has been shown to improve insulin resistance and hyperglycemia, and is in Phase III human clinical trials for the treatment of Cardiometabolic-Based Chronic Disease (CMBCD) by improving dysglycemia, dyslipidemia and hypertension.^[1]^[2]^[3]^[4]^[5]

References

S2CID 39205547
.

PMID 22543897
.

PMID 24586256
.

PMID 24672641
.

^ Clinical trial number NCT03254446 for "Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension. Torrent Pharmaceuticals Ltd." at ClinicalTrials.gov

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
v
t
e

Retrieved from "https://en.wikipedia.org/w/index.php?title=TRC-150094&oldid=1211069890"

[1] S2CID 39205547
.

[2] PMID 22543897
.

[3] PMID 24586256
.

[4] PMID 24672641
.

[5] Clinical trial number NCT03254446 for "Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension. Torrent Pharmaceuticals Ltd." at ClinicalTrials.gov

[1]

[2]

[3]

[4]

[5]